Anixa Biosciences, Inc , a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa’s novel breast cancer vaccine technology. This technology was invented and developed at Cleveland Clinic and Anixa is the exclusive worldwide licensee.
The patent is titled, “Vaccine Adjuvants and Formulations,” and the lead inventor is the late Dr. Vincent Tuohy, of Cleveland Clinic. This patent covers additional intellectual property related to the formulation of Anixa’s breast cancer vaccine.
Also Read: Life sciences lab automation provider Automata expands into the United States
“We are pleased to receive this notice of allowance from the USPTO, confirming additional protection of our breast cancer vaccine technology,” stated Dr. Amit Kumar, Chairman and CEO of Anixa. “This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer (“TNBC”), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin. With our partners at Cleveland Clinic, we are currently performing clinical trials of this vaccine, and plan to present data from the trial at the annual meeting of the American Association for Cancer Research in April.”
One in eight women in the U.S. will be diagnosed with an invasive breast cancer at some point in their lives. Approximately 10-15% of those diagnoses are TNBC, however TNBC accounts for a disproportionately higher percentage of breast cancer deaths and has a higher rate of recurrence. This form of breast cancer is twice as likely to occur in African-American women, and approximately 70% to 80% of the breast tumors that occur in women with mutations in the BRCA1 genes are triple-negative breast cancer.
SOURCE: PR Newswire